Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raymond Hupperts

Showing results (111-120 of 115) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 115 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 9, 2016
Contribution of different relapse phenotypes to disability in multiple sclerosisTamasine Stewart, Tim Spelman, Eva Havrdova, et al.
Plos One|May 25, 2013
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosisTomas Kalincik, Timothy Spelman, Maria Trojano, et al.
Brain : a Journal of Neurology|October 22, 2013
Sex as a determinant of relapse incidence and progressive course of multiple sclerosisTomas Kalincik, Vino Vivek, Vilija Jokubaitis, et al.
Neurology|December 29, 2020
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 YearsTomas Kalincik, Ibrahima Diouf, Sifat Sharmin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 10, 2019
Risk of secondary progressive multiple sclerosis: A longitudinal studyAdam Fambiatos, Vilija Jokubaitis, Dana Horakova, et al.
Pageof 12

Showing results (111-120 of 115) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 115 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 9, 2016
Contribution of different relapse phenotypes to disability in multiple sclerosisTamasine Stewart, Tim Spelman, Eva Havrdova, et al.
Plos One|May 25, 2013
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosisTomas Kalincik, Timothy Spelman, Maria Trojano, et al.
Brain : a Journal of Neurology|October 22, 2013
Sex as a determinant of relapse incidence and progressive course of multiple sclerosisTomas Kalincik, Vino Vivek, Vilija Jokubaitis, et al.
Neurology|December 29, 2020
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 YearsTomas Kalincik, Ibrahima Diouf, Sifat Sharmin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 10, 2019
Risk of secondary progressive multiple sclerosis: A longitudinal studyAdam Fambiatos, Vilija Jokubaitis, Dana Horakova, et al.
Pageof 12